Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies (Q37505840)

20 August 2017

1 reference

title

Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies (English)

1 reference

20 August 2017

1 reference

Janet B McGill

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

published in

Postgraduate Medicine

1 reference

20 August 2017

volume

121

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

16-25

1 reference

Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Is glycemic control improving in U.S. adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

beta-cell failure in diabetes and preservation by clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

The burden of treatment failure in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Potential of liraglutide in the treatment of patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.1998

21 January 2018

Identifiers

DOI

10.3810/PGM.2009.05.1998

1 reference

20 August 2017

1 reference